Investor Relations

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as a novel oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. In addition, we have clinical and preclinical programs based on the use of cyclophilin inhibitors to treat viral diseases, as well as contract research and development services primarily in the field of animal health.

$ 3.65 -0.11 (2.93%)
Day High: 3.81
Day Low:  3.60
Volume:    490,322
4:00 PM ET on
Oct 21, 2016

Delayed ~20 min., by eSignal.